TY - JOUR
TI - Pharmacokinetics of clarithromycin in the prostate: Implications for the
treatment of chronic abacterial prostatitis
AU - Giannopoulos, A
AU - Koratzanis, G
AU - Giamarellos-Bourboulis, EJ and
AU - Panou, C
AU - Adamakis, I
AU - Giamarellou, H
JO - Asian Journal of Urology
PY - 2001
VL - 165
TODO - 1
SP - 97-99
PB - Lippincott, Williams & Wilkins
SN - 2214-3882
TODO - 10.1097/00005392-200101000-00024
TODO - prostate; prostatitis; clarithromycin; pharmacokinetics
TODO - Purpose: We studied the pharmacokinetics of orally administered
clarithromycin in prostatic tissue to define its role in the treatment
of chronic abacterial prostatitis caused by intracellular pathogens.
Materials and Methods: A total of 45 men receiving 3 oral doses of 750
mg. clarithromycin at 12-hour intervals underwent suprapubic
prostatectomy for benign prostate hyperplasia 4, 5, 6 and 7 hours after
the last drug dose in 13, 12, 10 and 10 patients, respectively.
Concentrations were determined in the prostate tissue and in plasma by
an agar diffusion assay.
Results: A mean peak level of clarithromycin of 3.22 and 3.08 mug./gm.
of tissue was achieved 4 hours after the third drug dose at the center
and periphery of the adenoma, respectively. Tissue levels remained
statistically superior to plasma levels at all intervals.
Conclusions: The oral administration of clarithromycin achieved a
prostate level much higher than the minimal inhibitory concentration of
clarithromycin for the intracellular pathogens of chronic prostatitis.
Thus, clarithromycin may be considered for treating chronic abacterial
prostatitis.
ER -